Zealand Pharma AS
(OCSE:ZEAL)
kr
827
-18 (-2.13%)
Market Cap: 58.67 Bil
Enterprise Value: 50.13 Bil
PE Ratio: 0
PB Ratio: 6.38
GF Score: 61/100 Zealand Pharma A/S at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021 / 01:40PM GMT
Release Date Price:
kr195.4
(-0.20%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Okay. Good morning, everyone, and welcome to the 9:40 session on day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover European and U.S. biopharma names here at the firm. It's my great pleasure to be hosting Zealand Pharma in a fireside chat discussion today. And with us is Emmanuel Dulac, who is CEO of the company; and Matt Dallas, CFO of the company as well. And so with that, Emmanuel and Matt, welcome.
Matthew Donald Dallas;S;Senior VP;CFO
Zealand Pharma A
/-&
Thanks, Graig.
Emmanuel Dulac;S;CEO;President
Zealand Pharma A
/-&
Thank you, Graig.
Questions & Answers
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot